Man Group PLC Kodiak Sciences Inc. Transaction History

Man Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.81 - $8.88 $170,577 - $314,911	35,463 New	35,463 $219,000
Q2 2022 Aug 15, 2022	SELL	$5.04 - $9.48 $83,603 - $157,254	-16,588 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.09 - $89.45 $117,608 - $1.48 Million	16,588 New	16,588 $128,000
Q2 2021 Aug 16, 2021	SELL	$77.2 - $126.54 $2.61 Million - $4.28 Million	-33,791 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$110.45 - $164.47 $3.06 Million - $4.55 Million	-27,668 Reduced 45.02%	33,791 $3.83 Million
Q4 2020 Feb 16, 2021	SELL	$60.78 - $154.03 $2.01 Million - $5.09 Million	-33,043 Reduced 34.97%	61,459 $9.03 Million
Q3 2020 Nov 16, 2020	SELL	$45.05 - $59.27 $2.04 Million - $2.68 Million	-45,260 Reduced 32.38%	94,502 $5.6 Million
Q2 2020 Aug 14, 2020	BUY	$42.74 - $66.25 $5.97 Million - $9.26 Million	139,762 New	139,762 $7.56 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.